FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous  injection. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login